Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

This study tests whether adding a PARP inhibitor drug (talazoparib) to standard hormone-blocking therapy (androgen deprivation therapy plus abiraterone) helps men with newly metastatic prostate cancer that still responds to hormone treatment. **You may be eligible if...** - You have been diagnosed with prostate cancer that has spread to other parts of the body (bones or soft tissue) - Your cancer has not yet been treated with hormone therapy, or you started it very recently - Your diagnosis was confirmed by biopsy - You have adequate organ function and blood counts **You may NOT be eligible if...** - Your prostate cancer no longer responds to hormone therapy (castration-resistant) - You have had prior chemotherapy for prostate cancer - You have certain genetic conditions (like myelodysplastic syndrome) - You have significant heart or liver problems Talk to your doctor to see if this trial is right for you.